VYGR - Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform | Benzinga
H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR), noting a growing franchise of novel, highly-differentiated adeno-associated virus (AAV)-based TRACER capsids with the potential to overcome limitations of central nervous system (CNS) delivery and systemic toxicity of 1st-generation AAVs.
The analyst writes that Voyager’s TRACER capsid discovery platform has best-in-class potential for developing CNS-targeted in vivo gene therapies.
Voyager is advancing its Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) capsid discovery platform to develop novel capsids, the outer viral protein shells that enclose a genetic payload that makes up the gene therapy product, with enhanced affinity, to the CNS.
H.C. Wainwright notes that while gene therapy remains its core technology, Voyager’s pipeline also includes an anti-tau monoclonal antibody (mAb) ...